Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLT NASDAQ:CRIS NASDAQ:FBIO NASDAQ:SABS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$6.32-4.2%$6.07$5.20▼$15.60$12.65M0.8922,740 shs4,463 shsCRISCuris$1.84$2.11$1.02▼$8.29$19.25M3.6194,307 shs30,802 shsFBIOFortress Biotech$1.97+1.5%$1.88$1.33▼$2.60$57.37M1.75212,758 shs143,558 shsSABSSAB Biotherapeutics$2.55-1.9%$2.03$1.00▼$6.60$24.15M0.524.25 million shs210,713 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics-4.24%+14.29%+12.66%-18.97%-56.72%CRISCuris0.00%+2.22%-15.21%+12.88%-70.65%FBIOFortress Biotech+1.55%+1.03%+9.44%+20.12%-19.92%SABSSAB Biotherapeutics-1.92%-0.78%+43.26%+45.71%-12.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBOLTBolt Biotherapeutics2.7101 of 5 stars3.22.00.00.03.31.71.3CRISCuris2.5717 of 5 stars3.54.00.00.02.70.00.6FBIOFortress Biotech2.5057 of 5 stars3.51.00.00.02.23.30.6SABSSAB Biotherapeutics3.6868 of 5 stars3.55.00.00.03.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.33Hold$50.00691.14% UpsideCRISCuris 3.00Buy$17.00823.91% UpsideFBIOFortress Biotech 3.00Buy$21.00965.99% UpsideSABSSAB Biotherapeutics 3.00Buy$13.00409.80% UpsideCurrent Analyst Ratings BreakdownLatest CRIS, FBIO, SABS, and BOLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025SABSSAB BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $9.005/20/2025BOLTBolt BiotherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/19/2025CRISCurisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$17.005/15/2025SABSSAB BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/14/2025SABSSAB BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/13/2025BOLTBolt BiotherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$25.00 ➝ $20.00(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.69M1.58N/AN/A$29.89 per share0.21CRISCuris$10.91M1.76N/AN/A($0.71) per share-2.59FBIOFortress Biotech$57.67M1.01N/AN/A($0.06) per share-32.83SABSSAB Biotherapeutics$1.32M17.95N/AN/A$2.81 per share0.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$63.12M-$33.40N/AN/AN/AN/A-94.51%-59.07%8/12/2025 (Estimated)CRISCuris-$43.39M-$6.23N/AN/AN/A-376.08%N/A-97.14%7/30/2025 (Estimated)FBIOFortress Biotech-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)SABSSAB Biotherapeutics-$34.10M-$3.70N/AN/AN/AN/A-105.14%-69.24%8/6/2025 (Estimated)Latest CRIS, FBIO, SABS, and BOLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SABSSAB Biotherapeutics-$0.66N/AN/AN/AN/AN/A8/12/2025Q2 2025BOLTBolt Biotherapeutics-$6.40N/AN/AN/A$0.82 millionN/A8/12/2025Q2 2025FBIOFortress Biotech-$0.31N/AN/AN/A$14.53 millionN/A8/7/2025Q2 2025CRISCuris-$1.99N/AN/AN/AN/AN/A5/12/2025Q1 2025BOLTBolt Biotherapeutics-$6.80-$5.80+$1.00-$0.29$0.77 million$1.22 million5/9/2025Q1 2025SABSSAB Biotherapeutics-$1.00-$0.56+$0.44-$0.56$0.13 millionN/A5/6/2025Q1 2025CRISCuris-$1.14-$1.25-$0.11-$1.25$2.37 million$2.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt BiotherapeuticsN/AN/AN/AN/AN/ACRISCurisN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/ASABSSAB BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.483.133.13CRISCurisN/A1.231.23FBIOFortress Biotech1.741.721.55SABSSAB Biotherapeutics0.151.691.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%CRISCuris29.97%FBIOFortress Biotech96.51%SABSSAB Biotherapeutics7.82%Insider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics6.10%CRISCuris5.45%FBIOFortress Biotech27.90%SABSSAB Biotherapeutics27.77%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.80 millionNot OptionableCRISCuris6010.46 million9.89 millionNo DataFBIOFortress Biotech17029.57 million21.32 millionOptionableSABSSAB Biotherapeutics1409.29 million6.71 millionNot OptionableCRIS, FBIO, SABS, and BOLT HeadlinesRecent News About These CompaniesHC Wainwright Issues Positive Estimate for SABS EarningsJuly 26 at 2:29 AM | americanbankingnews.comSAB BIO Announces Oversubscribed $175 Million Private PlacementJuly 21, 2025 | globenewswire.comSABS - SAB Biotherapeutics Inc Sustainability | MorningstarJuly 19, 2025 | morningstar.comMSAB Biotherapeutics Holds Annual Stockholders MeetingJuly 18, 2025 | msn.comSAB Biotherapeutics Inc (SABS) - Investing.comJuly 8, 2025 | investing.comSABS - SAB Biotherapeutics Inc Chart - MorningstarJuly 4, 2025 | morningstar.comMSAB Biotherapeutics, Inc.: SAB BIO Announces Q1 2025 Financial Results and Provides Company UpdatesMay 9, 2025 | finanznachrichten.deSAB BIO Announces Q1 2025 Financial Results and Provides Company UpdatesMay 9, 2025 | globenewswire.comCraig-Hallum Reaffirms Their Buy Rating on SAB Biotherapeutics (SABS)April 3, 2025 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB BIO Reports Full Year 2024 Operating and Financial ResultsApril 2, 2025 | finanznachrichten.deSAB Biotherapeutics price target lowered to $20 from $25 at ChardanApril 2, 2025 | markets.businessinsider.comSAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024March 31, 2025 | markets.businessinsider.comSAB BIO Reports Full Year 2024 Operating and Financial ResultsMarch 31, 2025 | globenewswire.comSAB BIO to Participate in Upcoming Investor ConferencesJanuary 31, 2025 | globenewswire.comStrong Buy Recommendation for SAB-142: Promising Phase 1 Results and Future Market Potential in T1D TreatmentJanuary 29, 2025 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142January 29, 2025 | finanznachrichten.deSAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142January 28, 2025 | globenewswire.comSAB Biotherapeutics (SABS) Gets a Buy from Craig-HallumJanuary 24, 2025 | markets.businessinsider.comSAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D TherapyJanuary 23, 2025 | globenewswire.comHere’s Why SAB Biotherapeutics, Inc. (NASDAQ:SABS) Is Among the Best Diabetes Stocks to Buy Under $10January 6, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerBigBear.ai: Why a 90% Rally Could Be Just the StartBy Jeffrey Neal Johnson | July 10, 2025View BigBear.ai: Why a 90% Rally Could Be Just the StartThe Ultimate Trump Bump: These Gov't Backed Stocks Are ExplodingBy Leo Miller | July 2, 2025View The Ultimate Trump Bump: These Gov't Backed Stocks Are ExplodingCRIS, FBIO, SABS, and BOLT Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$6.32 -0.28 (-4.24%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$6.40 +0.08 (+1.27%) As of 07/25/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Curis NASDAQ:CRIS$1.84 0.00 (0.00%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.81 -0.03 (-1.85%) As of 07/25/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Fortress Biotech NASDAQ:FBIO$1.97 +0.03 (+1.55%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.97 0.00 (0.00%) As of 07/25/2025 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.SAB Biotherapeutics NASDAQ:SABS$2.55 -0.05 (-1.92%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.52 -0.03 (-1.37%) As of 07/25/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
